Advertisement

Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival

  • Heather A. Lillemoe
  • Yoshikuni Kawaguchi
  • Guillaume Passot
  • Georgios Karagkounis
  • Eve Simoneau
  • Yi-Qian Nancy You
  • Reza J. Mehran
  • Yun Shin Chun
  • Ching-Wei D. Tzeng
  • Thomas A. Aloia
  • Jean-Nicolas Vauthey
2018 SSAT Plenary Presentation
  • 83 Downloads

Abstract

Background

Recurrence rates are high for patients who have undergone two-stage hepatectomy (TSH) for bilateral colorectal liver metastases, and there is no established treatment approach for recurrent disease. This study aimed to determine the feasibility, safety, and prognostic impact of surgical resection for recurrence after TSH and the prognostic role of RAS mutation in this cohort.

Methods

The study included 137 patients intended to undergo TSH for bilateral colorectal metastases during 2003–2016. Clinicopathologic factors were compared using univariate and multivariate analyses.

Results

One hundred eleven patients (81%) completed TSH. The median recurrence-free survival in these patients was 12 months. Of the 83 patients with subsequent recurrence, 31 (37%) underwent resection for recurrence, and 11 underwent multiple resections for recurrence. Forty-eight operations were performed for recurrence: 23 repeat hepatectomies, 14 pulmonary resections, 5 locoregional resections, and 6 concurrent resections in multiple organ sites. The median overall survival (OS) among patients with recurrence was 143 months for patients who underwent resection and 49 months for those who did not (P < 0.001). On multivariate analysis, resection for recurrence (hazard ratio [HR] 0.25; 95% CI 0.10–0.54, P < 0.001) was associated with better OS, whereas RAS mutation (HR 2.25; 95% CI 1.16–4.50, P = 0.016) and first recurrence in multiple sites (HR 2.28; 95% CI 1.17–4.37, P = 0.016) were independent predictors of worse overall survival.

Conclusions

In patients who have undergone TSH for bilateral colorectal liver metastases, recurrence is frequent and should be treated with resection whenever possible. Patients with wild-type RAS fare particularly well with resection for recurrence.

Keywords

Colorectal neoplasms Hepatectomy Neoplasm metastases Recurrence 

Notes

Acknowledgements

The authors thank Stephanie Deming (Department of Scientific Publications, MD Anderson Cancer Center) for copyediting the manuscript and Ruth J Haynes (Department of Surgical Oncology, MD Anderson Cancer Center) for secretarial assistance in the preparation of the manuscript.

Funding Sources

Dr. Heather Lillemoe is supported by National Institutes of Health grant T32CA009599-29 and the MD Anderson Cancer Center support grant (P30 CA016672).

Statement of Author Contribution

  • Substantial contributions to:
    • The conception or design of the work: HL, YK, ES, JNV

    • The acquisition, analysis, or interpretation of data for the work: HL, YK, GP, GK, YY, RM, YSH, CWT, TA, JNV

  • Drafting the work or revising it critically for important intellectual content: All authors

  • Final approval of the version to be published: All authors

  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All authors

References

  1. 1.
    Adam R, Laurent A, Azoulay D et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232: 777–785.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Passot G, Chun YS, Kopetz SE et al. Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases. J Am Coll Surg 2016; 223: 99–108.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Brouquet A, Abdalla EK, Kopetz S et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29: 1083–1090.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Wicherts DA, Miller R, de Haas RJ et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008; 248: 994–1005.CrossRefPubMedGoogle Scholar
  5. 5.
    Narita M, Oussoultzoglou E, Jaeck D et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br J Surg 2011; 98: 1463–1475.CrossRefPubMedGoogle Scholar
  6. 6.
    Lam VW, Laurence JM, Johnston E et al. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford) 2013; 15: 483–491.CrossRefGoogle Scholar
  7. 7.
    Blazer DG, 3rd, Kishi Y, Maru DM et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344–5351.CrossRefPubMedGoogle Scholar
  8. 8.
    Passot G, Vauthey JN. In favor of two-stage hepatectomy (TSH). Eur J Surg Oncol 2015; 41: 1566–1567.CrossRefPubMedGoogle Scholar
  9. 9.
    Vakiani E, Janakiraman M, Shen R et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30: 2956–2962.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mullen JT, Ribero D, Reddy SK et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204: 854–862; discussion 862-854.CrossRefPubMedGoogle Scholar
  12. 12.
    Imai K, Benitez CC, Allard MA et al. Impact of surgical treatment for recurrence after 2-stage hepatectomy for colorectal liver metastases, on patient outcome. Ann Surg 2017.  https://doi.org/10.1097/SLA.0000000000002472.
  13. 13.
    Vauthey JN, Zimmitti G, Kopetz SE et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258: 619–626; discussion 626-617.CrossRefPubMedGoogle Scholar
  14. 14.
    Schirripa M, Bergamo F, Cremolini C et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 2015; 112: 1921–1928.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chun YS, Passot G, Yamashita S et al. Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases. Ann Surg 2017.  https://doi.org/10.1097/SLA.0000000000002450.
  16. 16.
    Margonis GA, Spolverato G, Kim Y et al. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol 2015; 22: 4158–4165.CrossRefPubMedGoogle Scholar
  17. 17.
    Kemeny NE, Chou JF, Capanu M et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 2014; 120: 3965–3971.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kim MJ, Lee HS, Kim JH et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 2012; 12: 347.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Pereira AA, Rego JF, Morris V et al. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 2015; 112: 424–428.CrossRefPubMedGoogle Scholar
  20. 20.
    Carlsson U, Lasson A, Ekelund G. Recurrence rates after curative surgery for rectal carcinoma, with special reference to their accuracy. Dis Colon Rectum 1987; 30: 431–434.CrossRefPubMedGoogle Scholar
  21. 21.
    Yeo HL, Paty PB. Management of recurrent rectal cancer: practical insights in planning and surgical intervention. J Surg Oncol 2014; 109: 47–52.CrossRefPubMedGoogle Scholar
  22. 22.
    Adam R, de Gramont A, Figueras J et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 2015; 41: 729–741.CrossRefPubMedGoogle Scholar
  23. 23.
    You YN, Skibber JM, Hu CY et al. Impact of multimodal therapy in locally recurrent rectal cancer. Br J Surg 2016; 103: 753–762.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Colibaseanu DT, Mathis KL, Abdelsattar ZM et al. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis? Dis Colon Rectum 2013; 56: 14–19.CrossRefPubMedGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2018

Authors and Affiliations

  • Heather A. Lillemoe
    • 1
  • Yoshikuni Kawaguchi
    • 1
  • Guillaume Passot
    • 1
  • Georgios Karagkounis
    • 1
  • Eve Simoneau
    • 1
  • Yi-Qian Nancy You
    • 1
  • Reza J. Mehran
    • 2
  • Yun Shin Chun
    • 1
  • Ching-Wei D. Tzeng
    • 1
  • Thomas A. Aloia
    • 1
  • Jean-Nicolas Vauthey
    • 1
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Thoracic and Cardiovascular SurgeryThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations